AMSBIO offer an extensive range of aptamers targeting many human proteins linked to cancer. Aptamers bind to target molecules with the same affinity and specificity as antibodies but offer significant advantages, in particular a lack of immunogenicity, which makes them an ideal tool for cancer diagnosis and therapy.
There are two major applications for aptamers in cancer therapy. Aptamers can be used as antagonists by targeting and inhibiting cancer-specific molecules. They can also be used as delivery vehicles for therapeutics by specifically targeting cell membrane receptors on cancer cells. In this application, aptamer-drug conjugates bind to and are internalized by cancer cells while avoiding damage to healthy cells.
Aptamers also have enormous potential for use in cancer diagnostics. They can be used to identify cancer cells and recognize cancer biomarkers, cancer metabolites and differentiating cells as well as molecules that affect tumor behavior. New aptamer-based technologies such as cell-SLEX are increasingly being used to screen for aptamers that bind to cancer cell-surface protein biomarkers as they overcome the traditional shortfalls of mass spectrometry and antibody-based methods - cross-reactivity, poor reproducibility, complexity, and high cost.
For further information and a list of available aptamer targets linked to cancer please visit https://www.amsbio.com/aptamers-for-cancer/ or contact AMSBIO on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / email@example.com.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery (lentivirus, adenovirus, and adeno-associated virus.
Illustrative image : (avalable on request)
Caption: Aptamers for cancer diagnosis and therapy